We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
-5.96%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$4.19B
AUM Growth
-$667M
Cap. Flow
-$151M
Cap. Flow %
-3.6%
Top 10 Hldgs %
47.69%
Holding
131
New
13
Increased
16
Reduced
22
Closed
21

Top Buys

Rank Stock Value
1
PFE icon
Pfizer
PFE
+$101M
2
SION
Sionna Therapeutics
SION
+$60.5M
3
AXSM icon
Axsome Therapeutics
AXSM
+$44.1M
4
APLS
Apellis Pharmaceuticals
APLS
+$39.6M
5
UNH icon
UnitedHealth
UNH
+$35.9M

Top Sells

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$117M
2
MRK icon
Merck
MRK
+$82.6M
3
BIIB icon
Biogen
BIIB
+$77.9M
4
ISRG icon
Intuitive Surgical
ISRG
+$61.2M
5
UHS icon
Universal Health Services
UHS
+$48.3M

Sector Composition

Rank Sector Weight
1 Healthcare 98.96%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KZR
101
DELISTED
Kezar Life Sciences
KZR
$940K 0.02%
192,700
– –
TNGX icon
102
Tango Therapeutics
TNGX
$4.34B
$754K 0.02%
550,000
– –
IVVD icon
103
Invivyd
IVVD
$175M
$565K 0.01%
933,500
-215,800
-19% -$194K
KRRO icon
104
Korro Bio
KRRO
$151M
$564K 0.01%
32,400
– –
NXTC icon
105
NextCure
NXTC
$22.1M
$548K 0.01%
95,100
– –
ANRO icon
106
Alto Neuroscience
ANRO
$1.07B
$540K 0.01%
250,000
– –
DHAI
107
DELISTED
DIH Holdings US
DHAI
$443K 0.01%
+76,600
New +$1.42M
XERS icon
108
Xeris Biopharma Holdings
XERS
$1.42B
$442K 0.01%
80,420
– –
LSB
109
DELISTED
LakeShore Biopharma
LSB
$344K 0.01%
140,428
– –
BIIB icon
110
Biogen
BIIB
$30.4B
– –
-509,100
Closed -$77.9M
CCCC icon
111
CALL
C4 Therapeutics
CCCC
$393M
– –
-150,000
Closed -$540K
ELEV
112
DELISTED
Elevation Oncology
ELEV
– –
-941,275
Closed -$530K
GERN icon
113
Geron
GERN
$930M
– –
-2,168,000
Closed -$7.67M
GILD icon
114
CALL
Gilead Sciences
GILD
$167B
– –
-200,000
Closed -$18.5M
IMVT icon
115
Immunovant
IMVT
$7.99B
– –
-78,500
Closed -$1.94M
LYEL icon
116
Lyell Immunopharma
LYEL
$318M
– –
-155,181
Closed -$1.99M
MEDP icon
117
Medpace
MEDP
$15.9B
– –
-44,900
Closed -$14.9M
MIST icon
118
Milestone Pharmaceuticals
MIST
$133M
– –
-2,000,000
Closed -$4.72M
MLYS icon
119
Mineralys Therapeutics
MLYS
$2.38B
– –
-1,611,637
Closed -$19.8M
MRK icon
120
Merck
MRK
$326B
– –
-829,900
Closed -$82.6M
NMRA icon
121
Neumora Therapeutics
NMRA
$311M
– –
-804,996
Closed -$8.53M
PEPG icon
122
PepGen
PEPG
$127M
– –
-653,016
Closed -$2.47M
SIBN icon
123
CALL
SI-BONE Inc
SIBN
$795M
– –
-250,000
Closed -$3.5M
SRPT icon
124
Sarepta Therapeutics
SRPT
$1.63B
– –
-963,400
Closed -$117M
THC icon
125
CALL
Tenet Healthcare
THC
$22.6B
– –
-25,000
Closed -$3.16M
2 3 4
5
6

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

OrbiMed's Q1 2025 Portfolio in Review

As of Q1 2025, OrbiMed held 131 positions worth $4.19B, down 14% from $4.86B the previous quarter. Its ten largest holdings account for 48% of the portfolio.

OrbiMed withdrew a net $151M in Q1 2025, closing 21 positions and reducing 22 holdings. Its most notable exit was Sarepta Therapeutics, an estimated $117M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 98% a quarter earlier.

Against the trend, OrbiMed opened a new position in Pfizer worth $97.6M.

  • OrbiMed's largest Q1 2025 buy was Pfizer: 3,850,200 shares worth $97.6M.
  • OrbiMed added most to UnitedHealth in Q1 2025, an estimated $35.9M increase.
  • OrbiMed's biggest Q1 2025 reduction was Intuitive Surgical, cutting an estimated $61.2M.
  • OrbiMed fully exited Sarepta Therapeutics in Q1 2025, selling an estimated $117M.
  • OrbiMed's ten largest holdings make up 48% of its $4.19B portfolio in Q1 2025.
  • OrbiMed opened 13 new positions and closed 21 in Q1 2025.
  • OrbiMed's portfolio value fell 14% quarter-over-quarter to $4.19B.

Based on OrbiMed's 13F filing for Q1 2025, filed 15 May 2025.